The estimated Net Worth of Helen Katrina Tayton Martin is at least 5.5 百万$ dollars as of 3 March 2021. Helen Martin owns over 1,785,000 units of Adaptimmune Therapeutics Plc stock worth over 1,944,000$ and over the last 9 years he sold ADAP stock worth over 2,198,000$. In addition, he makes 1,355,090$ as Chief Business Officer at Adaptimmune Therapeutics Plc.
Sign up
Helen Martin ADAP stock SEC Form 4 insiders trading
Helen has made over 3 trades of the Adaptimmune Therapeutics Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,785,000 units of ADAP stock worth 285,600$ on 3 March 2021.
The largest trade he's ever made was exercising 1,785,000 units of Adaptimmune Therapeutics Plc stock on 3 March 2021 worth over 285,600$. On average, Helen trades about 173,750 units every 35 days since 2016. As of 3 March 2021 he still owns at least 1,800,000 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Helen Martin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Helen Tayton-Martin biography
Dr. Helen Katrina Tayton-Martin Ph.D. serves as Chief Business Officer of the Company. She was Chief Operating Officer of the Company. Dr. Tayton-Martin has 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She formerly served as Chief Operating Officer and is a co-founder of Adaptimmune, joining from Avidex Limited (subsequently Medigene) where she was responsible for commercial development of the soluble TCR program in cancer and HIV therapy. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.
What is the salary of Helen Martin?
As the Chief Business Officer of Adaptimmune Therapeutics Plc, the total compensation of Helen Martin at Adaptimmune Therapeutics Plc is 1,355,090$. There are 3 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of 2,821,740$.
How old is Helen Martin?
Helen Martin is 53, he's been the Chief Business Officer of Adaptimmune Therapeutics Plc since 2017. There are 13 older and 6 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
What's Helen Martin's mailing address?
Helen's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Insiders trading at Adaptimmune Therapeutics Plc
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over 40,532,026$ worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth 527,131,726$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of 2,827,332$. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth 22,814$.
What does Adaptimmune Therapeutics Plc do?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
What does Adaptimmune Therapeutics Plc's logo look like?
Complete history of Helen Martin stock trades at Adaptimmune Therapeutics Plc、Trillium Therapeutics Inc
Adaptimmune Therapeutics Plc executives and stock owners
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include:
-
James Noble,
Non-Executive Director -
Adrian Rawcliffe,
Chief Executive Officer, Director -
William Bertrand,
Chief Operating Officer -
Helen Tayton-Martin,
Chief Business Officer -
Adrian G. Rawcliffe,
CEO, Principal Accounting Officer & Director -
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.,
Co-Founder & Chief Bus. Officer -
William C. Bertrand Jr.,
Chief Operating Officer -
Gavin Hilary James Wood BA (Hons), ACA,
Chief Financial Officer -
David Mott,
Non-Executive Independent Chairman of the Board -
Tal Zvi Zaks,
Non-Executive Independent Director -
Elliott Sigal,
Non-Executive Independent Director -
John Furey,
Non-Executive Independent Director -
Barbara Duncan,
Non-Executive Independent Director -
Ali Behbahani,
Non-Executive Independent Director -
Lawrence Alleva,
Non-Executive Independent Director -
John Lunger,
Chief Patient Supply Officer -
Elliot Norry,
Senior Vice President, Chief Medical Officer -
Gavin Wood,
Chief Financial Officer -
Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
Sr. VP of Clinical Devel. -
Dr. Rafael G. Amado,
Pres of R&D -
Sébastien Desprez,
VP of Communications & Corp. Affairs -
Margaret Henry,
Head of PR & Company Sec. -
Dr. Juli P. Miller Ph.D.,
VP of Investor Relations -
Ravi Viswanathan,
10% owner -
Scott D Sandell,
10% owner -
Gwendolyn Knowlton Binder S...,
EVP, Adaptimmune LLC -
Giles Francis Bertram Kerr,
Director -
Jonathan Kenneth Charles Kn...,
Director -
Forest Baskett,
10% owner -
Ian Michael Laing,
Director -
Rafael Amado,
President, R&D -
Peter A. Thompson,
Director -
Peter W. Sonsini,
10% owner -
Patrick J Kerins,
10% owner -
Anthony A. Jr. Florence,
10% owner -
M James Barrett,
10% owner -
Enterprise Associates 14, L...,
-
Advisors Llc Orbi Med Capit...,
-
Peter J Barris,
10% owner -
Advisors Llc Orbi Med Capit...,
-
Kristen Hege,
Director -
Priti Hegde,
Director -
Andrew R Allen,
Director -
Cintia Piccina,
Chief Commercial Officer -
Joanna Elizabeth Brewer,
Chief Scientific Officer -
Garry E Menzel,
Director